Published in Nat Immunol on May 31, 2009
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med (2011) 4.50
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 3.51
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A (2010) 2.88
Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet (2010) 2.74
Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol (2009) 2.43
Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med (2010) 2.35
B cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 2.25
Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity (2011) 2.11
Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 1.94
Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.93
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal (2010) 1.66
Interleukin-27: balancing protective and pathological immunity. Immunity (2012) 1.58
Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (2011) 1.56
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Interleukin-17 and its expanding biological functions. Cell Mol Immunol (2010) 1.55
Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A (2010) 1.49
Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle (2010) 1.47
Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol (2014) 1.47
Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog (2014) 1.39
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Redundant or separate entities?--roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res (2010) 1.35
Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol (2009) 1.34
Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol (2011) 1.33
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity (2012) 1.30
Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol (2012) 1.27
Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol (2010) 1.27
Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PLoS One (2013) 1.23
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine (2014) 1.21
IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J Immunol (2010) 1.21
Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics (2011) 1.20
Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol (2011) 1.19
BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol (2009) 1.18
Lupus nephritis: lessons from murine models. Nat Rev Rheumatol (2009) 1.18
Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.16
CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J Clin Invest (2014) 1.14
The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res (2011) 1.14
Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther (2010) 1.13
IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol Rev (2010) 1.12
Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther (2011) 1.09
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Targeting BAFF in autoimmunity. Curr Opin Immunol (2010) 1.08
Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics (2012) 1.08
IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer. Lab Invest (2010) 1.07
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol (2012) 1.06
Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest (2013) 1.05
Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis (2010) 1.04
IL-17 in systemic lupus erythematosus. J Biomed Biotechnol (2010) 1.04
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol (2014) 1.03
Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther (2013) 1.03
Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One (2011) 1.02
IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol (2012) 1.02
The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica (2011) 1.01
Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol (2013) 1.01
The role of cytokines in Guillain-Barré syndrome. J Neurol (2010) 1.00
Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol (2009) 0.99
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol (2011) 0.99
IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol (2014) 0.97
Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1. J Immunol (2011) 0.97
CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol (2016) 0.97
IL-17A and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin Dev Immunol (2013) 0.97
Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells (2013) 0.97
Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity. Cell Mol Immunol (2010) 0.96
Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (2010) 0.96
Selected Aspects in the Pathogenesis of Autoimmune Diseases. Mediators Inflamm (2015) 0.95
Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol (2013) 0.95
Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol (2012) 0.95
IL-17 inhibits adipogenesis in part via C/EBPα, PPARγ and Krüppel-like factors. Cytokine (2013) 0.94
Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PLoS One (2010) 0.94
Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J Autoimmun (2012) 0.94
Identification of Baicalin as an immunoregulatory compound by controlling T(H)17 cell differentiation. PLoS One (2011) 0.94
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol (2013) 0.93
Expression of interleukin-22 in Sjögren's syndrome: significant correlation with disease parameters. Scand J Immunol (2011) 0.93
Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J Clin Immunol (2013) 0.93
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis. Future Virol (2012) 0.93
Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 (2015) 0.92
Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med (2012) 0.92
IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol (2015) 0.92
B-cell activating factor targeted therapy and lupus. Arthritis Res Ther (2012) 0.92
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One (2011) 0.91
B cell signature during inactive systemic lupus is heterogeneous: toward a biological dissection of lupus. PLoS One (2011) 0.90
Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Res Ther (2012) 0.90
Cyclin-dependent kinase inhibitor Cdkn2c deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus. J Immunol (2012) 0.90
Sleep disorders and increased risk of autoimmune diseases in individuals without sleep apnea. Sleep (2015) 0.89
The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum (2010) 0.89
Vicious circle: systemic autoreactivity in Ro52/TRIM21-deficient mice. J Exp Med (2009) 0.89
Interleukin 17A promotes gastric cancer invasiveness via NF-κB mediated matrix metalloproteinases 2 and 9 expression. PLoS One (2014) 0.88
Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis (2013) 0.88
The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One (2012) 0.88
Contributions of B cells to lupus pathogenesis. Mol Immunol (2013) 0.87
The rationale for BAFF inhibition in systemic lupus erythematosus. Curr Rheumatol Rep (2012) 0.87
Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun (2013) 0.87
Estrogen increases, whereas IL-27 and IFN-gamma decrease, splenocyte IL-17 production in WT mice. Eur J Immunol (2010) 0.87
Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease. Discov Med (2011) 0.86
The Fas death factor. Science (1995) 13.81
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Fas and Fas ligand: lpr and gld mutations. Immunol Today (1995) 4.69
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 3.72
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 3.65
Identification and characterization of circulating human transitional B cells. Blood (2005) 3.62
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell (2003) 3.40
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev (1999) 3.25
Twist is a potential oncogene that inhibits apoptosis. Genes Dev (1999) 3.14
Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus (2000) 3.08
Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol (2008) 3.03
Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol (2006) 2.94
BAFF: a fundamental survival factor for B cells. Nat Rev Immunol (2002) 2.94
NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A (1999) 2.83
Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev (1999) 2.82
Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol (2008) 2.57
Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity (2008) 2.48
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 2.47
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol (2008) 1.99
Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol (2008) 1.96
Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol (2007) 1.88
IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol (2008) 1.73
Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A (2008) 1.66
Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol (2007) 1.54
Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol (2008) 1.51
Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ (2003) 1.48
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol (2009) 1.40
Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene (2007) 1.35
Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine (2007) 1.31
Ets-1 regulates plasma cell differentiation by interfering with the activity of the transcription factor Blimp-1. J Biol Chem (2007) 1.29
Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis (2008) 1.23
A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc Natl Acad Sci U S A (2008) 1.19
TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol (2008) 1.15
Comparison of 12 reference genes for normalization of gene expression levels in Epstein-Barr virus-transformed lymphoblastoid cell lines and fibroblasts. Mol Diagn Ther (2006) 1.12
Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol (2008) 1.02
Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a novel programmed cell death. J Immunol (1992) 1.01
B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus. Ann N Y Acad Sci (2005) 0.96
Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus. Lupus (2007) 0.95
B cells flying solo. Immunol Cell Biol (2008) 0.94
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (2010) 3.47
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol (2007) 2.83
Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve (2010) 2.78
Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet (2004) 2.67
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum (2013) 2.60
A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol (2010) 2.46
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int (2011) 2.34
Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med (2007) 2.21
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum (2011) 1.83
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine (2006) 1.77
A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol (2003) 1.77
A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol (2012) 1.75
ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest (2013) 1.74
Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell (2004) 1.71
Both extrauterine and intrauterine growth restriction impair renal function in children born very preterm. Kidney Int (2009) 1.70
Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation (2003) 1.69
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat (2010) 1.67
Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med (2013) 1.63
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis (2008) 1.53
INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med (2011) 1.53
Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol (2008) 1.52
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood (2004) 1.50
Correlations between clinical, histologic, blood, and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. J Invest Dermatol (2003) 1.50
Congenital versus acquired solitary kidney: is the difference relevant? Nephrol Dial Transplant (2010) 1.50
Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol (2006) 1.50
Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer (2009) 1.49
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol (2007) 1.47
Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine (2010) 1.46
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol (2010) 1.43
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab (2010) 1.42
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet (2007) 1.41
Paediatric conferences: only a profit making enterprise? Acta Paediatr (2012) 1.41
Hyperuricemia after liver transplantation in children. Pediatr Transplant (2008) 1.41
Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore) (2002) 1.41
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer (2007) 1.40
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int (2011) 1.39
Munchausen syndrome by proxy with massive proteinuria and gastrointestinal hemorrhage. Pediatr Nephrol (2004) 1.36
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell (2013) 1.35
The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells (2010) 1.34
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol (2009) 1.32
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant (2011) 1.29
Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol (2006) 1.29
Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant (2008) 1.27
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) (2014) 1.26
Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene (2003) 1.25
Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat (2006) 1.25
Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2010) 1.23
Genetic screening in adolescents with steroid-resistant nephrotic syndrome. Kidney Int (2013) 1.21
Pseudohypoaldosteronisms, report on a 10-patient series. Nephrol Dial Transplant (2008) 1.21
TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J Immunol (2009) 1.20
Mutations of NPHP2 and NPHP3 in infantile nephronophthisis. Kidney Int (2009) 1.19
Schimke immunoosseous dysplasia: suggestions of genetic diversity. Hum Mutat (2007) 1.19
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther (2004) 1.17
Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem (2009) 1.17
Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine (2006) 1.16
Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database. Hum Mutat (2012) 1.15
Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation (2006) 1.15
From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat (2011) 1.14
p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol (2006) 1.14
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica (2012) 1.13
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Toxoplasma seroprevalence in a rural population in France: detection of a household effect. BMC Infect Dis (2009) 1.11
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
Disease recurrence in paediatric renal transplantation. Pediatr Nephrol (2009) 1.10
Serum creatinine improves body mass index survival prediction in hemodialysis patients: a 1-year prospective cohort analysis from the ARNOS study. J Ren Nutr (2011) 1.09
Neurodevelopmental deficits in Pierson (microcoria-congenital nephrosis) syndrome. Am J Med Genet A (2007) 1.09